BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18070050)

  • 1. p53 and Ki-67 expression in renal cell carcinomas of pregnant women and their correlation with prognosis: a pilot study.
    Pomara G; Salinitri G; Nesi G; Maio E; Minervini A; Gammazza AM; Francesca F; Cappello F; Selli C
    Int J Gynecol Cancer; 2008; 18(1):132-5. PubMed ID: 18070050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-metastatic clear cell renal carcinoma: prognostic significance of morphometric and biomolecular factors].
    Iurin AG
    Vopr Onkol; 2009; 55(2):177-82. PubMed ID: 19514371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
    Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
    J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma.
    Kanamaru H; Li B; Miwa Y; Akino H; Okada K
    Urol Res; 1999 Jun; 27(3):169-73. PubMed ID: 10422817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
    Sejima T; Miyagawa I
    Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
    Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
    Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
    Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
    Cho DS; Joo HJ; Oh DK; Kang JH; Kim YS; Lee KB; Kim SJ
    Yonsei Med J; 2005 Feb; 46(1):133-40. PubMed ID: 15744816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
    Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
    BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
    Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
    Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical study of bcl-2, p53 and Ki-67 expressions in collecting duct carcinoma of the kidney. Five cases and review of the literature on bcl-2, p53 and Ki-67 expressions in renal cell carcinoma and transitional cell carcinoma.
    Suzuki K; Tokue A
    Urol Int; 2002; 69(1):57-62. PubMed ID: 12119441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma.
    Baytekin F; Tuna B; Mungan U; Aslan G; Yorukoglu K
    Urol Oncol; 2011; 29(5):502-7. PubMed ID: 19945306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
    Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
    Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma.
    Teng J; Gao Y; Chen M; Wang K; Cui X; Liu Y; Xu D
    Chin Med J (Engl); 2014; 127(9):1640-4. PubMed ID: 24791867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.
    Virman JP; Bono P; Luukkaala TH; Sunela KL; Kujala PM; Kellokumpu-Lehtinen PL
    Clin Genitourin Cancer; 2016 Aug; 14(4):e283-9. PubMed ID: 26821530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy.
    Sakai I; Miyake H; Takenaka A; Fujisawa M
    BJU Int; 2009 Oct; 104(7):942-6. PubMed ID: 19388989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
    Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
    J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.